207Users Online
Animal Healthcare Market Segmented By Anti-Infective Agents | Antibiotics & Antimicrobials (Anti-Fungal, Anti-Viral, Anti-Inflammatory & Analgesic Agents) | Parasiticides (Endo-Parasiticides, Ecto-Parasiticides, Endectocides) | Vaccines | Hormones & Substitutes | Nutritional Products
The global revenue from the animal healthcare market stands atUS$ 39.1 Bnin 2022, with the global market expected to grow at a CAGR of3.9%to reach a valuation of approximatelyUS$ 60.3 Bnby the end of 2033.
Market Size (2022) |
US$ 39.1 Bn |
Projected Market Value (2033) |
US$ 60.3 Bn |
Global Market Growth Rate (2023-2033) |
3.9% CAGR |
Market Share of Top 5 Countries |
46.4% |
As assessed by Persistence Market Research, parasiticides are expected to hold a market value of aroundUS$15.0 Bnby 2033. Overall, animal healthcare market sales account for approximately45.0%revenue share in theglobal veterinary services market, which was valued at aroundUS$ 86.8 Bnin 2022.
Free Report Sample is Available!
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The global market recorded a historic CAGR of4.5%in the last 10 years from 2012 to 2022.
Manufacturers of animal health products are biopharmaceutical firms that spend money on R&D to develop innovative drugs for pets and livestock. To protect the wellbeing and security of animals, people, and the food supply, the animal health industry works in collaboration with ranchers and farmers, government organisations, veterinary professionals, and other groups.
It is impossible to separate the health of all animals from that of people and the environment. Animals in better health require less natural resources, which enables them to produce more food, labour, fertiliser, companionship, and aid with less feed, drink, and land.
更强的免疫力,改善预防措施,earlier and more accurate diagnosis, and more precise and efficient treatment are some of the innovations in animal health that are on the horizon that can reduce the threat of diseases.
The implementation of these improvements will result in lower emissions, a more efficient use of natural resources, and fewer animal deaths. Despite the promise of expanding veterinarian knowledge and skill, animal health companies are finding it more and more difficult and expensive to introduce new products to the market.
Early disease identification and individually tailored therapies can have a positive impact on both animal health and sustainable development. This includes lowering the costs associated with treating sick animals and promoting agricultural productivity all over the world, enhancing diagnostic and treatment precision to cut down on the need for antibiotics and safeguard public health, and reducing the spread of zoonotic diseases that affect both humans and animals.
Additionally, enhancing animal health through precise nutrition, feed additives, and bio parasiticides has numerous advantages for animal health and wellbeing in addition to promoting higher sustainability. Research and development for new products can be made safer and more animal welfare-friendly by implementing measures of evaluating novel therapies or treatments, which use fewer animals.
The global market is thus likely to show high growth over the coming years at a CAGR of3.9%and reach a global market size ofUS$ 60.3 Bnby 2033.
Make This Report Your Own!
Take Advantage of Intelligence Tailored to your Business Objective
Request A Customized Version“Development of Novel Vaccine Platforms, and Setting Regulatory Flexibility”
The effectiveness and precision of mass immunisation can be enhanced by new vaccine platforms. Systems that provide vaccines to day-old chicks on a conveyor belt or within the egg prior to hatching, for instance, can increase the immunisation rate of poultry.
Oral vaccinations and newly developed automated injection devices enable efficient protection in aquaculture while avoiding time-consuming manual injections. Farmers can get protection that is particularly customised to their livestock and environment thanks to autogenous vaccines. When a veterinarian suspects that a herd is harbouring a disease strain for which conventional immunizations would not be effective, they may seek for an autogenous vaccine.
The manufacturer will develop a vaccine customized to that specific virus strain using a herd culture sample, which can help significantly in protecting farm animals that are uninfected.
更大的监管灵活性可能会加快development of vaccines and delivery platforms. By gaining more acceptability, a master dossier might be used to approve a basic vaccine technology initially, allowing subsequent evaluations to concentrate on the innovative or unique features of each vaccine application.
Furthermore, promoting businesses to submit a single dossier for a vaccine encompassing multiple strains would improve the agility and flexibility to address various disease threats in various geographic locations.
Regulators could improve the options for demonstrating efficacy and safety while lowering the number of study animals required by creating standards for novel testing procedures such in vitro testing and eliminating pointless batch safety testing.
These factors will promote the opportunities for the market to expand, over the forecast period.
“Laborious Regulatory Approval Activity and Short Patent Protection Period”
Over fifty different animal species require the administration of veterinary medicines and health products for disease prevention, diagnosis, and treatment. It is difficult to develop innovations that operate in this diversified context, and it is therefore crucial that the policy and regulatory framework take into account the industry's specific attributes.
It can take between five and fifteen years after a novel drug or product is discovered before it can be used to treat animals, and since 2015, this period has gotten longer in Europe.
In the meanwhile, the chance to return this investment is time-limited unless a product is patent-protected, especially in the case of livestock. Companies in Europe have ten years of data protection following the approval of a new product for sale.
In the US, data protection is only in place for five years, most of which can be covered by the process for setting international standards. For instance, before a product can be employed by manufacturers who want to export, Maximum Residue Levels (MRLs) for trade must be established.
This means that before the innovator can see a return on their investment, a product may already have lost its exclusivity protection by the time it can be broadly utilized and be up against generic competition.
In addition, after a product is approved for sale, the animal health industry frequently adopts Good Manufacturing Practices (GMP) that are designed for human health. Without modified GMP, an animal health product would be subject to pointless regulations that might make its production unprofitable.
Despite efforts to unify rules by groups like the Veterinary International Conference on Harmonization, many regions still have seemingly heterogeneous regulatory standards. For instance, different markets may demand different numbers of animals be included in trials to prove safety and efficacy, and manufacturers must meet these standards.
Smaller markets may not be able to recover their investments once a product is granted approval due to these regulatory expenditures, which makes it unlikely that a business will ever submit it for evaluation. As a result, veterinarians, farmers, and pet owners have fewer tools at their disposal.
All these factors restrain the growth of the overall market, and continue to do so over the forecast period.
为什么美国动物保健市场蓬勃发展?
“Large Number of People with Companion Animals, and Growth of the Livestock Industry”
The U.S. accounted for around84.3%market share in the North America market in 2022. According to the American Health Institute, almost 400 million pets, including cats, dogs, horses, birds, fishes, and more, are owned by more than 67% of American homes.
The production of meat and dairy products for domestic and international consumers is also based on healthy livestock, which benefits the American economy and provides people with wholesome, inexpensive food.
Farmers and ranchers employ medications to preserve the wellbeing of animals used for food production, safeguard public health, and safeguard the food supply. These elements are accelerating the growth of the international market in the country and are anticipated to do so for the upcoming years.
Will Germany Be a Lucrative Market for Animal Healthcare?
“Guidelines and Reimbursements by the European Commission”
Germany held around18.6%market share of the Europe market in 2022. For all European citizens, animal health is a concern. This concern is brought on by the public health and food safety components of animal health, as well as the financial consequences that animal disease epidemics can bring about and the considerations for the wellbeing of animals, including the effects of disease control.
The major goal of current compensation plans is to give pet owners a way to get compensated in the event of a disease epidemic. The strategy's main goals may be greatly aided by an equitable distribution of costs, rewards, and responsibilities.
On the one hand, governments must play a crucial part in protecting the country's borders from disease invasions and organising the response to exotic disease epidemics. This factor aids the growth of the market in Germany.
How is China Emerging as a Prominent Market for Animal Healthcare?
“Rising Investments in Animal Healthcare”
China held a market share of about5.4%of the global market in 2022. China's regulatory environment has changed during the last five years, and this has both benefited and hampered innovation. By inviting businesses to remark on new regulatory requirements, Chinese authorities and executives have generally shown increased transparency in the policy-making process.
Multinational animal health companies are increasingly establishing R&D and/or manufacturing operations or facilities in China. This is partly attributable to the government's initiatives to support China's veterinary pharmaceutical industry, which have allowed more domestic players from international corporations to emerge over the past five years as a driving force for investments in those sectors.
这药物是推动民主党and within the Global Market?
“Effectiveness of Parasiticides”
Parasiticides dominated the global market in 2022 and are expected to hold a market value of aroundUS$15.0 Bnby 2033. Ivermectin and moxidectin are also suitable against arthropod parasites. In veterinary medicine, the term "parasiticide" refers to anthelmintic medications. Anthelmintics are drugs that can make parasitic intestinal worms leave the body. The only anthelmintics authorised for use in organic animal production are fenbendazole, ivermectin, and moxetectin.
感染寄生虫,fenbendazole ivermectin, and moxidectin are particularly effective. Management of parasiticide resistance has grown to be a significant issue in animal health. Increased parasiticide resistance could result from increased usage of anthelmintics in cattle production, thus driving the segment share within the global market.
Which Animal is Largely of Focus within the Global Market?
“Increasing Demand for Animal Based Proteins”
Farm animals held a share of about60.0%in 2022. Agriculture and animal husbandry are essential to human nutrition. The emergence of middle classes in developing nations and their new consumption patterns will contribute to the increase in demand for animal protein. New difficulties in disease control will arise as a result of the consequent growth in animal production.
Thus, the management of farm animals owed to the increasing demand foranimal-based productshave propelled the growth of this segment within the global market.
Which Route of Administration is Highly Adopted in the Global Market?
“Stability of Oral Medication Forms and Ease of Administration”
The oral route of administration held a share of about44.4%in 2022. Many livestock farmers provide drenches, oral treatments, and regular vaccines for their own horses and cattle. When administering pills in the form of oral medications to cattle, balling guns are employed.
These medicines typically come in pill or liquid form. Moreover, the most typical dosage forms for giving medications to dogs and cats are traditional and chewable pills. Since tablets have the potential to be more chemically and physically stable than liquid forms, oral administration is frequently adopted.
Which Distribution Channel Generally Promotes Market Growth?
“Availability of an Array of Veterinary Services”
Veterinary hospitals hold a share of about34.1%in 2022. Clinical services provided by veterinary clinics include the care of sick animals and the management of production-limiting conditions.
Preventive services include the halting of disease outbreaks and the distribution of medications, vaccines, and other products. Human health protection includes the testing of commercially available animal products.
Given the increasing threat of zoonotic disease spread, the veterinary clinics offer a variety of services to prevent and manage veterinary disease outbreaks.
Top businesses are concentrating on increasing regional acquisitions as a result of market consolidation. Latin America as well as Asian nations like China and India have noticed the trend.
The firms that control the acquisition market are those with a significant regional marketing footprint in terms of a direct sales force and local GMP-certified production facilities supported by qualified labour.
Some key instances of development include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the animal healthcare market, which are available in the full report.
Attribute |
Details |
Forecast Period |
2023-2033 |
Historical Data Available for |
2012-2022 |
Market Analysis |
USD Million for Value |
Key Countries Covered |
|
Key Market Segments Covered |
|
Key Companies Covered |
|
Report Coverage |
|
Customization & Pricing |
Available upon Request |
Drugs:
Animals:
给药途径:
Distribution Channel:
Region:
The global market is currently valued at aroundUS$ 39.1 Bnin 2022.
Sales of the market are set to witness growth at a CAGR of3.9%and be valued at aroundUS$ 60.3 Bnby 2033.
Demand for the global market increased at a4.5%CAGRfrom 2012 to 2022.
The U.S., China, Canada, Germany, and France account for most demand within the market, currently holding around46.4%market share.
The U.S. accounts for around84.3%shareof the North American market in 2022.
Latin America accounts for around11.7%shareof the global market in 2022.
China held a market share of about5.4%of the global market in 2022.
Germany held around18.6%market share of the Europe market in 2022.
The Brazil market is expected to grow at a4.3%CAGR during the forecast period.
The animal healthcare market in India is set to expand at a5.6%CAGR over the forecast period.
